Alnylam Pharmaceuticals, Inc.
ALNY
$332.92
$1.680.51%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.10B | 1.25B | 773.69M | 594.19M | 593.17M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.10B | 1.25B | 773.69M | 594.19M | 593.17M |
| Cost of Revenue | 267.72M | 200.15M | 142.95M | 71.04M | 102.82M |
| Gross Profit | 829.31M | 1.05B | 630.74M | 523.15M | 490.35M |
| SG&A Expenses | 325.37M | 322.08M | 323.31M | 239.95M | 295.34M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 965.32M | 881.04M | 789.89M | 576.11M | 698.33M |
| Operating Income | 131.72M | 367.98M | -16.20M | 18.08M | -105.16M |
| Income Before Tax | 161.14M | 238.97M | -35.36M | -41.60M | -193.96M |
| Income Tax Expenses | -25.28M | -12.12M | 30.92M | 15.88M | -110.20M |
| Earnings from Continuing Operations | 186.42M | 251.08M | -66.28M | -57.48M | -83.76M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 186.42M | 251.08M | -66.28M | -57.48M | -83.76M |
| EBIT | 131.72M | 367.98M | -16.20M | 18.08M | -105.16M |
| EBITDA | 145.22M | 381.79M | -2.26M | 32.48M | -90.99M |
| EPS Basic | 1.41 | 1.91 | -0.51 | -0.44 | -0.65 |
| Normalized Basic EPS | 0.58 | 1.32 | -0.16 | -0.20 | -0.94 |
| EPS Diluted | 1.37 | 1.84 | -0.51 | -0.44 | -0.65 |
| Normalized Diluted EPS | 0.56 | 1.27 | -0.16 | -0.20 | -0.94 |
| Average Basic Shares Outstanding | 132.23M | 131.45M | 130.63M | 129.68M | 129.12M |
| Average Diluted Shares Outstanding | 136.28M | 137.35M | 130.63M | 129.68M | 129.12M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |